Durect corporation doses first european patient in phase 2b ahfirm study of larsucosterol(dur-928) in severe alcohol-associated hepatitis

Cupertino, calif., march 1, 2022 /prnewswire/ -- durect corporation (nasdaq: drrx) today announced it dosed the first patient in the european union as part of its ahfirm randomized, double-blind, placebo-controlled, multi-center phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (ah) patients.
DRRX Ratings Summary
DRRX Quant Ranking